Lamotrigine ODT (Orange) (Lamotrigine) Patent Expiration, LOE Window & CMS Spending

Lamotrigine ODT (Orange) (Lamotrigine) by Endo Pharmaceuticals: Multi-Source Generic Molecule, 36 AB generics, $151K 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorEndo Pharmaceuticals
FDA Application & PathwayReconciled (ANDA)
Exclusivity / Cliff HorizonMulti-Source Generic Molecule
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors36
2024 CMS Total Public Spend$151K
2024 Medicare Part D Spend$29K
2024 Medicaid Spend$123K
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel